CD79A and COVID-19: Reports that critical illness in COVID-19 is associated with higher serum levels of IgG and IgA antibodies to SARS-CoV-2 spike protein (SP) (42–45), have raised the possibility that antibody responses against SARS-CoV-2 might be a determinant of the immunopathology in patients with COVID-19.